Somnath Dutta

Prof. Somnath Dutta

Molecular Biophysics Unit, Indian Institute of Science Bangalore, Bengaluru, India

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2019 in Nature
Verified
Journal Article
Closed access
PDF file
AKAntoine Koehl
Antoine Koehl
HHHongli Hu
Hongli Hu
DFDan Feng
Dan Feng
BSBingfa Sun
Bingfa Sun
YZYan Zhou
Yan Zhou
BKBrian K. Kobilka
Brian K. Kobilka

1 September 2019 in Cell Reports
Verified
Journal Article
Open access
EGEshan Ghosh
Eshan Ghosh
HDHemlata Dwivedi
Hemlata Dwivedi
MBMithu Baidya
Mithu Baidya
ASAshish Srivastava
Ashish Srivastava
PKPunita Kumari
Punita Kumari
ASArun K. Shukla
Arun K. Shukla
Desensitization, signaling, and trafficking of G-protein-coupled receptors (GPCRs) are critically regulated by multifunctional adaptor proteins, β-arrestins (βarrs). The two isoforms of βarrs (βarr1 and 2) share a high degree of sequence and structural similarity; still, however, they often mediate distinct functional outcomes in the context of GPCR signaling and regulation. A mechanistic basis for such a functional divergence of βarr isoforms is still lacking. By using a set of complementary approaches, including antibody-fragment-based conformational sensors, we discover structural differences between βarr1 and 2 upon their interaction with activated and phosphorylated receptors. Interestingly, domain-swapped chimeras of βarrs display robust complementation in functional assays, thereby linking the structural differences between receptor-bound βarr1 and 2 with their divergent functional outcomes. Our findings reveal important insights into the ability of βarr isoforms to drive distinct functional outcomes and underscore the importance of integrating this aspect in the current framework of biased agonism.

15 February 2019 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
SKSanjeev Kumar
Sanjeev Kumar
HPHarekrushna Panda
Harekrushna Panda
MMMuzamil Ashraf Makhdoomi
Muzamil Ashraf Makhdoomi
NMNitesh Mishra
Nitesh Mishra
HSHaaris Ahsan Safdari
Haaris Ahsan Safdari
KLKalpana Luthra
Kalpana Luthra
Broadly neutralizing antibodies (bNAbs) have demonstrated protective effects against HIV-1 in primate studies and recent human clinical trials. Elite neutralizers are potential candidates for isolation of HIV-1 bNAbs. The coexistence of bNAbs such as BG18 with neutralization-susceptible autologous viruses in an HIV-1-infected adult elite controller has been suggested to control viremia. Disease progression is faster in HIV-1-infected children than in adults. Plasma bNAbs with multiple epitope specificities are developed in HIV-1 chronically infected children with more potency and breadth than in adults. Therefore, we evaluated the specificity of plasma neutralizing antibodies of an antiretroviral-naive HIV-1 clade C chronically infected pediatric elite neutralizer, AIIMS_330. The plasma antibodies showed broad and potent HIV-1 neutralizing activity with >87% (29/33) breadth, a median inhibitory dilution (ID50) value of 1,246, and presence of N160 and N332 supersite-dependent HIV-1 bNAbs. The sorting of BG505.SOSIP.664.C2 T332N gp140 HIV-1 antigen-specific single B cells of AIIMS_330 resulted in the isolation of an HIV-1 N332 supersite-dependent bNAb, AIIMS-P01. The AIIMS-P01 neutralized 67% of HIV-1 cross-clade viruses, exhibited substantial indels despite limited somatic hypermutations, interacted with native-like HIV-1 trimer as observed in negative stain electron microscopy, and demonstrated high binding affinity. In addition, AIIMS-P01 neutralized the coexisting and evolving autologous viruses, suggesting the coexistence of vulnerable autologous viruses and HIV-1 bNAbs in the AIIMS_330 pediatric elite neutralizer. Such pediatric elite neutralizers can serve as potential candidates for isolation of novel HIV-1 pediatric bNAbs and for understanding the coevolution of virus and host immune response. IMPORTANCE More than 50% of the HIV-1 infections globally are caused by clade C viruses. To date, there is no effective vaccine to prevent HIV-1 infection. Based on the structural information of the currently available HIV-1 bNAbs, attempts are under way to design immunogens that can elicit correlates of protection upon vaccination. Here, we report the isolation and characterization of an HIV-1 N332 supersite-dependent bNAb, AIIMS-P01, from a clade C chronically infected pediatric elite neutralizer. The N332 supersite is an important epitope and is one of the current HIV-1 vaccine targets. AIIMS-P01 potently neutralized the contemporaneous and autologous evolving viruses and exhibited substantial indels despite low somatic hypermutations. Taken together with the information on infant bNAbs, further isolation and characterization of bNAbs contributing to the plasma breadth in HIV-1 chronically infected children may help provide a better understanding of their role in controlling HIV-1 infection.

1 August 2018 in Trends in Cell Biology
Verified
Journal Article
Closed access
HSHaaris Ahsan Safdari
Haaris Ahsan Safdari
SPShubhi Pandey
Shubhi Pandey
ASArun K. Shukla
Arun K. Shukla
Somnath DuttaSomnath Dutta
Somnath Dutta

1 January 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SMSameer Kumar Malladi
Sameer Kumar Malladi
RSRandhir Singh
Randhir Singh
SPSuman Pandey
Suman Pandey
SGSavitha Gayathri
Savitha Gayathri
KKKawkab Kanjo
Kawkab Kanjo
RVRaghavan Varadarajan
Raghavan Varadarajan
Virtually all SARS-CoV-2 vaccines currently in clinical testing are stored in a refrigerated or frozen state prior to use. This is a major impediment to deployment in resource-poor settings. Furthermore, several of them use viral vectors or mRNA. In contrast to protein subunit vaccines, there is limited manufacturing expertise for these nucleic-acid-based modalities, especially in the developing world. Neutralizing antibodies, the clearest known correlate of protection against SARS-CoV-2, are primarily directed against the receptor-binding domain (RBD) of the viral spike protein, suggesting that a suitable RBD construct might serve as a more accessible vaccine ingredient. We describe a monomeric, glycan-engineered RBD protein fragment that is expressed at a purified yield of 214 mg/l in unoptimized, mammalian cell culture and, in contrast to a stabilized spike ectodomain, is tolerant of exposure to temperatures as high as 100 °C when lyophilized, up to 70 °C in solution and stable for over 4 weeks at 37 °C. In prime:boost guinea pig immunizations, when formulated with the MF59-like adjuvant AddaVax, the RBD derivative elicited neutralizing antibodies with an endpoint geometric mean titer of ∼415 against replicative virus, comparing favorably with several vaccine formulations currently in the clinic. These features of high yield, extreme thermotolerance, and satisfactory immunogenicity suggest that such RBD subunit vaccine formulations hold great promise to combat COVID-19.

1 August 2021 in Structure
Verified
Journal Article
Closed access
IPIshika Pramanick
Ishika Pramanick
NSNayanika Sengupta
Nayanika Sengupta
SMSuman Mishra
Suman Mishra
SPSuman Pandey
Suman Pandey
NGNidhi Girish
Nidhi Girish
Somnath DuttaSomnath Dutta
Somnath Dutta